Destiny Pharma’s recent capital market day (CMD) has highlighted the opportunity for its XF-73 anti-infective treatment, says house broker Shore Capital.
Physicians detailed the increasing infection threat with an increase in the prevalence of resistant bacteria posing a particular problem.
Emphasis was placed on the issues surrounding the use of standard-of-care topical antibiotic mupirocin, which suffers from mounting resistance and the need for a prolonged dosing window which hampers patient compliance and complicates integration into clinical practice.
In contrast, XF-73 possesses several key attributes which effectively address all of these issues and suggest that it can provide a truly effective and potentially best-in-class treatment, added the broker.
Breast cancer was one of the areas of potential infection highlighted during the CMD.
Surgery patients here are at an elevated risk of suffering from post-surgical infections often as a consequence of the tumour being excised and additional surgery to the lymph nodes required.
“Post the capital markets day our peak sales forecast of $1bn in the US alone looks increasingly conservative.”
All eyes are now on the ability of the company to attract a partner to fund Phase 3 development and to ensure that XF-73’s market potential is maximised, particularly in the key US market, Shore concluded.